Abiomed (NASDAQ: ABMD) is a global technology leader focused on RECOVERING HEARTS AND SAVING LIVES.
The Company's portfolio of heart support and recovery products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the catheterization lab to the surgical suite, together with interventional cardiologists and surgeons, Abiomed is dedicated to providing the most advanced medical technologies to heart patients, with the ultimate goal of heart recovery and improved quality of life.
Abiomed was founded more than two decades ago and is the only company in the world with exclusive labeling on ventricular assist devices for all potentially recoverable heart failure indications. More >> |  | |
| Date | Title | | | 02/04/10 | Abiomed Reports Third Quarter Fiscal 2010 Financial Results| U.S. Commercial Impella Revenue of $14.5 Million, Up 116%DANVERS, Mass., Feb 04, 2010 (BUSINESS WIRE) -- Abiomed,
Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart
support technologies, today reported third quarter fiscal 2010 revenue
of $22.8 million, up 32% compared to revenue of $17.3 million for the
same period of fiscal 2009.
Financial and operating highlights during the third quarter of fiscal
2010 include:
U.S. co... |
|  | | 01/28/10 | Abiomed Third Fiscal Quarter 2010 Earnings and Conference Call
Notification| DANVERS, Mass., Jan 28, 2010 (BUSINESS WIRE) -- Abiomed,
Inc. (NASDAQ: ABMD) announced today that on Thursday, February 4,
2010, the Company will release financial results for the third quarter
of fiscal 2010. The Company will host a conference call to discuss the
results on Thursday, February 4, 2010, at 8:00 a.m. ET. Michael R.
Minogue, Chairman, President and Chief Executive Officer and Robert L.
Bowen, Vice President and Chief Financial Officer... |
| | | 01/27/10 | Abiomed Announces Partnership with Opsens to Utilize Sensor
Technology for Impella| DANVERS, Mass., Jan 27, 2010 (BUSINESS WIRE) -- Abiomed,
Inc. (NASDAQ: ABMD) ("Abiomed"), a leading provider of breakthrough
heart support technologies designed for heart recovery, today announced
a strategic partnership with Opsens (TSX VENTURE EXCHANGE: OPS)
("Opsens"), a leading developer of fiber optic sensors. Through this
partnership, Opsens' breakthrough sensor technology will be integrated
into the Impella(R) catheter to provide robust bloo... |
| | | 01/25/10 | Impella 2.5 Patient Procedure at Mount Sinai Medical Center Featuring New Product Enhancements:Webcast Available| DANVERS, Mass., Jan 25, 2010 (BUSINESS WIRE) -- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced the webcast of a Impella(R) 2.5 procedure featuring new product enhancements at Mount Sinai Medical Center. The webcast is now available and archived on the Abiomed website (www.abiomed.com).
The webcast was broadcasted live from Mount Sinai Medical Center on January 19, 2010 and presents a successful high-risk percutaneous coronary interv... |
| |
|
| | | * Data collected 02/14/10 - 02/21/10 |
|
|
|
| There are currently no events scheduled. |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
| Minimum 20 minutes delayed |
|
